Background
Embrex, Inc. held an exclusive license to U.S. Patent No. 4,458,630, which claimed methods of vaccinating poultry by injecting vaccines into eggs before they hatch — a process known as in ovo vaccination. The invention allowed mass immunization of chicks while still in the egg, dramatically reducing labor costs and disease spread in commercial poultry operations.
Service Engineering Corp. (SEC) and its principal, Edward Bounds, were attempting to develop their own in ovo injection device. During that development effort, SEC conducted tests using equipment and methods that fell within the scope of Embrex’s patent claims. SEC argued that its activities were protected by the common-law experimental use exception — the judge-made doctrine that purely experimental, non-commercial use of a patented invention does not constitute infringement. The district court rejected that defense, found willful infringement, and awarded treble damages and attorney fees.
The Court’s Holding
The Federal Circuit affirmed the infringement finding and confirmed that the experimental use exception did not apply. Writing for the panel, the court emphasized that the experimental use doctrine is exceedingly narrow — it covers only actions done “for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry,” not activities undertaken to further a commercial enterprise.
SEC’s tests were performed in furtherance of its business plan to build and sell an in ovo injection system. The fact that SEC was experimenting to develop a competing product, rather than immediately selling an infringing product, did not remove the infringement from the commercial sphere. The court made clear that the exception does not apply when the defendant’s ultimate goal is commercial — even if that commercial goal has not yet been realized.
The court also affirmed the willfulness finding and the exceptional-case award of attorney fees, noting that SEC continued its infringing activities after receiving notice from Embrex and without any reasonable basis for believing its conduct was non-infringing.
Key Takeaways
- The common-law experimental use exception to patent infringement is extremely narrow and does not shelter activities with any commercial motivation or purpose.
- Testing a patented method to develop a competing product is patent infringement even if no infringing products have yet been sold.
- Continuing to use a patented invention after receiving a cease-and-desist notice — without a good-faith basis for believing non-infringement — supports a finding of willful infringement.
- Willful infringement can justify treble damages and an exceptional-case finding that shifts attorney fees to the infringer.
- Companies seeking to design around a patent should obtain a written freedom-to-operate opinion from patent counsel before beginning any testing or development work.
Why It Matters
Embrex sharply defines the boundaries of a defense that many startups and researchers mistakenly assume gives them broad freedom to experiment with patented technology. The ruling makes clear that the only truly safe zone for using someone else’s patent without a license is pure, non-commercial academic inquiry — and even that narrow zone was later tightened further in Madey v. Duke University (2002), where the Federal Circuit held that a university’s research activities could not claim the experimental use exception because the university itself has institutional commercial interests.
For businesses, Embrex stands as a reminder that product development programs that necessarily involve practicing a patented claim require either a license or a credible invalidity or non-infringement position. The decision remains a leading citation in any discussion of the limits of the experimental use doctrine in U.S. patent law.